Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis
Key Highlights
- ➤Quantum BioPharma (QNTM) signs Study Start-Up Agreement with Thermo Fisher’s PPD clinical research business
- ➤FDA clearance moves Lucid-MS into formal Phase 2 study start-up activities
- ➤PPD will provide trial implementation, study start-up, and related clinical research services
- ➤Lucid-MS Phase 2 will evaluate efficacy, safety, and tolerability in progressive MS
- ➤Trial uses randomized, double-blind, placebo-controlled design with clinical and radiological endpoints
Expert Statements
Zeeshan Saeed, Chief Executive Officer of Quantum BioPharma
“We are pleased to enter into a contract with the clinical research business of Thermo Fisher as we advance the Lucid-MS program toward Phase 2”
Andrzej Chruscinski, President, Scientific and Clinical Affairs at Quantum BioPharma
“Lucid-MS is designed around a novel neuroprotective approach that targets demyelination rather than solely modulating the immune system.”
Andrzej Chruscinski, President, Scientific and Clinical Affairs at Quantum BioPharma
“The Phase 2 study will provide an important opportunity to evaluate this approach using clinical and radiological measures.”
Andrzej Chruscinski, President, Scientific and Clinical Affairs at Quantum BioPharma
“Entering into the Study Start-Up Agreement allows us to begin the operational work required, and we look forward to working closely with Thermo Fisher and our clinical investigators as the program advances.”
Michael Cioffi, Vice President and General Manager, Neuroscience, Clinical Research, Thermo Fisher
“We’re proud to partner with Quantum BioPharma in advancing their neuro-degenerative clinical program in multiple sclerosis”
Michael Cioffi, Vice President and General Manager, Neuroscience, Clinical Research, Thermo Fisher
“Our team brings deep experience in CNS and MS trials, along with an integrated approach that connects strategy and execution to help deliver these complex studies.”
Michael Cioffi, Vice President and General Manager, Neuroscience, Clinical Research, Thermo Fisher
“By combining scientific expertise with operational excellence, we can help bring promising new therapies closer to the patients who need them.”
TORONTO, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company focused on developing innovative therapies and technologies, today announced that it has entered into a Study Start-Up Agreement (“SUA”) with the clinical research business of Thermo Fisher Scientific to implement Quantum’s Phase 2 clinical trial of Lucid-21-302 (“Lucid-MS”) for multiple sclerosis (“MS”).
The execution of the contract represents an important milestone in the clinical development of Lucid-MS and marks the initiation of formal study start-up activities. Following the Company’s receipt of FDA clearance to proceed with the planned Phase 2 clinical trial, Quantum BioPharma is advancing into implementation.
Get started
Create a free account to read the full story.